Clinical trials: Baseline
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease
The main objective of this study is to evaluate the efficacy of satralizumab compared with placebo based on time from randomization to the first occurrence of an adjudicated MOGAD relapse in the double-blind (DB) treatment…
- Trial name
- Meteoroid (NCT05271409)
- Testing
- Satralizumab
- Where
- 53 sites in United States, Australia and 9 more
- Volunteers
- 139 people
- Sponsor
- Hoffmann-La Roche
Myopia, Progressive
Slow Myopia Progression With Different Irradiance Light
It is a prospective clinical control study on red light control myopia with specail design spectacles for 75 children in 3 groups. Study Groups with two different powers of 0.6 mW and 1.2 mW at wavelength of 650nm.
- Trial name
- NCT05881655
- Testing
- Airdoc Red Lighting Device, Special Spectacles to Control Myopia
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Beijing Airdoc Technology Co., Ltd.
Hypercholesterolemia
Ezetimibe/Simvastatin (10 mg/40 mg) vs. the Doubling of Atorvastatin in High Risk Participants (MK-0653A-134 AM1)(COMPLETED)
Participants currently taking atorvastatin 20 mg will be switched to either atorvastatin 40 mg or ezetimibe/simvastatin 10 mg/40 mg (10/40).
- Trial name
- NCT00782184
- Testing
- ezetimibe/simvastatin 10/40, atorvastatin 40 mg, atorvastatin 20 mg
- Volunteers
- 250 people
- Sponsor
- Organon and Co
Myelodysplastic Syndrome
A Phase II Pilot Study to Assess the Presence of Molecular Factors Predictive for Hematologic Response in Myelodysplastic Syndrome Patients Receiving Deferasirox Therapy.
Several previous studies (clinical and non-clinical) hypothesize that treatment with deferasirox causes a hematological improvement in transfused patients with low and intermediate-1 risk myelodysplastic syndrome.
- Trial name
- EXPHAR (NCT02663752)
- Testing
- Bone marrow aspirate, Deferasirox
- Where
- Belgium
- Volunteers
- 1 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
Comparison of Two Treatment Strategies in Hypertensive Patients
The purpose of the study is to determine whether a specific training of General Practitioners (Family Physicians) regarding the new official guidelines for the treatment of hypertension results in a higher control of high Blood…
- Trial name
- NCT00171444
- Testing
- Medical education
- Volunteers
- 4,445 people
- Sponsor
- Novartis
Hearing Loss, Ear Diseases
Baseline Performance and Fitting Parameters for Sonova Products
The purpose of this study is to assess the effectiveness and optimization of various FDA approved products.
- Conditions
- Hearing Loss, Ear Diseases, Hearing Disorders, Otolaryngological Disease
- Trial name
- NCT05859568
- Testing
- Pinna-located microphone, Pinna-simulated microphone algorithm
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Advanced Bionics
Influenza
Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the 2010/2011 Season
Influenza (flu) viruses change continuously, therefore also the parts of viruses used in influenza vaccines can vary from year to year.
- Trial name
- NCT01146015
- Testing
- Trivalent influenza subunit vaccine Influvac
- Where
- 2 sites in Belgium, Germany
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- Abbott Biologicals
BRAF Positive Metastatic Melanoma
Real-world Evaluation of the Impact of Baseline Metastases on Clinical Outcomes Among BRAF Positive Metastatic Melanoma Patients
This was a retrospective real-world evidence cohort study.
- Trial name
- NCT05984615
- Where
- United States
- Volunteers
- 1,961 people
- Sponsor
- Novartis Pharmaceuticals
Prophylaxis of Influenza
Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the 2012/2013 Season
Annual study to investigate influenza vaccine (flu vaccine) developed for the 2012/2013 season for the prevention of influenza infection. The immunizing effect is being investigated, as well as its tolerability and safety.
- Trial name
- NCT01633749
- Testing
- Trivalent influenza subunit vaccine Influvac
- Where
- Germany
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Abbott Biologicals
Coronary Artery Disease, Dyslipidemia
The Study of Quantitative Serial Trends in Lipids With ApolpoproteinA-I Stimulation
This study is designed to provide an assessment of the change in baseline lipid parameters with RVX000222 after 12 weeks and 24 weeks of treatment when given in addition to optimized statin background therapy in subjects with low…
- Trial name
- SUSTAIN (NCT01423188)
- Testing
- RVX000222
- Where
- 25 sites in South Africa
- Volunteers
- 176 people
- Sponsor
- Resverlogix Corp
Epilepsy
Eslicarbazepine Acetate as Add-On Treatment to One Baseline Antiepileptic Drug (ESLADOBA)
This is a multicenter, non-interventional, prospective study. The observation period comprises at least 6 months, from the initiation of ESL add-on therapy in adult patients with partial-onset epilepsy not sufficiently controlled…
- Trial name
- NCT01532726
- Testing
- ESL
- Where
- Portugal
- Volunteers
- 56 people
- Sponsor
- Bial - Portela C S.A.
Essential Hypertension
Study of CS-3150 Compared to Olmesartan in Patients With Essential Hypertension
Phase 3 study to examine the relation between antihypertensive effect and baseline factors exploratively, compared to olmesartan medoxomil in patients with essential hypertension.
- Trial name
- NCT02848170
- Testing
- CS-3150, olmesartan medoxomil
- Where
- Japan
- Volunteers
- 40 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
HR+/HER2- Advanced or Metastatic Breast Cancer
A Descriptive Study of Baseline Characteristics, Clinical Outcomes, and Treatment Patterns of HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Alpelisib Plus Fulvestrant Who Have Received Fulvestrant in Any Prior Line of Therapy
This was a non-interventional, retrospective cohort study of patients with HR+/HER2- aBC treated with alpelisib (ALP) plus fulvestrant (FUL) who have received fulvestrant in any prior line of therapy (LoT).
- Trial name
- NCT05853432
- Where
- Ireland
- Volunteers
- 157 people
- Sponsor
- Novartis Pharmaceuticals
Fabry Disease
A Study to Learn How Well Lucerastat Works and How Safe it is in Untreated Adult Male Participants With Fabry Disease
The purpose of this clinical trial is to learn how well lucerastat works and how safe it is in untreated adult male participants with Fabry disease.
- Trial name
- Fab-Klear (NCT07778667)
- Testing
- Lucerastat
- Volunteers
- 16 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
HIV Infections
A Comparison of Two Anti-HIV Triple-Drug Combinations in HIV-Infected Patients
The purpose of this study is to compare the safety and effectiveness of two anti-HIV drug combinations when given to HIV-infected patients who have never been treated with anti-HIV drugs.
- Trial name
- NCT00002168
- Testing
- Indinavir sulfate, Lamivudine, Stavudine
- Where
- 13 sites in United States, Puerto Rico
- Volunteers
- 200 people
- Sponsor
- Bristol-Myers Squibb
Hemodynamic Monitoring
Starling/CRRT Observational Study
Hemodynamic optimization of critically ill patients is a goal for clinicians in order to afford the patient the best possible outcomes.
- Trial name
- NCT05729048
- Testing
- Starling
- Where
- United States
- Sponsor
- Baxter Healthcare Corporation
Gut Dysbiosis, Telogen Effluvium
Gut Microbiota and Trichoscopic Changes in Women With Telogen Effluvium on a Multifactorial Drinkable Nutraceutical: A Retrospective Observational Study
Telogen effluvium (TE) is a common cause of diffuse, non-scarring hair shedding in women. It is often triggered by physiological stress, nutritional deficiencies, illness or hormonal changes.
- Conditions
- Gut Dysbiosis, Telogen Effluvium, Hair Loss
- Trial name
- NCT07869199
- Testing
- Drinkable multifactorial food supplement containing vitamins, minerals, plant extracts, and other bioactive compounds, formulated to support hair growth and scalp health in women.
- Where
- 2 sites in Spain
- Volunteers
- 30 people
- Sponsor
- Olistic Research Labs S.L.
X-Linked Adrenoleukodystrophy
A Study to Prospectively Assess Disease Progression in Male Children With X-ALD
This is a non-interventional, multi-center study that follows general principles of periodic assessment of X-ALD patients in routine practice.
- Trial name
- NCT03278899
- Where
- 3 sites in United States
- Volunteers
- 100 people
- Sponsor
- NeuroVia, Inc.
Hypogonadotropic Hypogonadism
Luveris® (Lutropin Alfa for Injection) in Women With Hypogonadotropic Hypogonadism (Luteinizing Hormone [LH] Less Than [<] 1.2 International Unit Per Liter [IU/L])
Sponsor has decided to discontinue Luveris® in the United States (US) due to level of customer demand for this product, and not due to any efficacy or safety concerns.
- Trial name
- NCT00328926
- Testing
- Luveris® 75 IU, Luveris® 25 IU, Recombinant human follicle stimulating hormone (r-hFSH)
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- EMD Serono
Dyslipidemias
A Study Of Atorvastatin For The Treatment Of High Cholesterol In Patients At High Risk Of Coronary Heart Disease (CHD)
A study of the long-term (1 year) effectiveness of atorvastatin to keep patients of high cardiovascular risk at the LDL cholesterol goal of <115 mg/dL
- Trial name
- NCT00644709
- Testing
- Atorvastatin
- Where
- 15 sites in Belgium
- Volunteers
- 196 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.